May 08, 2025
Immunoglobulin light chain (LC) amyloidosis (AL) is one of the most common types of systemic amyloidosis but there is no reliable in vivo model for better…
May 05, 2025
Panelists discuss how early diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) relies on clinical awareness, recognizing red flag symptoms, and utilizing…
Apr 28, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the…
Apr 05, 2025
Although SGLT2 inhibitors have become standard in the management of heart failure with preserved and reduced ejection fraction, their use in patients with ATTR…
Apr 05, 2025
AbstractWe report a case of dual amyloidosis with Alzheimer's disease and wild-type transthyretin (ATTRwt) amyloidosis. A 76-year-old man with Alzheimer's disease…
Apr 02, 2025
Key takeaways:Vutrisiran improved all-cause mortality and recurrent CV independent of disease severity in cardiac amyloidosis.Regardless of cutoffs, vutrisiran also…
Apr 01, 2025
Last month, March 2025, the CGTLive® team was diligently tracking the FDA's activities related to the development of cell and gene therapies for the treatment of…
Mar 20, 2025
Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and HealthcareRNA interference (RNAi) therapeutics have garnered significant…
Mar 17, 2025
All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…
Mar 13, 2025
AbstractClinical genetic testing often takes days to weeks, but rapid, affordable tests during outpatient visits could significantly benefit patients. This is…